ClinicalTrials.gg
RecruitingNCT07653048PHEBiPUpdated Jun 17, 2026

Personality Traits and Biochemical Risk Phenotypes

An observational study in Prediabetes, Hyperglycemia and Metabolic Syndrome, sponsored by Medical Center TOPMED. Recruiting at 1 site in Romania. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Medical Center TOPMED · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

This prospective observational study investigates the association between personality traits and routine laboratory abnormalities in adults undergoing routine health assessment. Personality traits are assessed using the Five-Factor Personality Inventory (FFPI), while biochemical data are obtained from routine laboratory testing, including markers of glycemic status, liver function, lipid metabolism, renal function, and complete blood count parameters.

The primary objective of the study is to evaluate the association between FFPI personality trait scores and the total number of laboratory abnormalities identified during routine clinical evaluation. Secondary analyses will examine associations between personality traits and glycemic status, fasting plasma glucose concentration, liver function markers, lipid profile parameters, renal function indicators, complete blood count parameters, and the total number of laboratory abnormalities.

The findings may contribute to a better understanding of the relationship between psychological characteristics and biological health indicators and may support the development of more personalized approaches to health promotion, risk assessment, and disease prevention.

Read the detailed description

The study is designed as a prospective observational cohort investigation conducted in adults undergoing routine health assessment. Participants complete the Five-Factor Personality Inventory (FFPI), and clinical and laboratory data are collected as part of routine medical evaluation.

Routine laboratory assessment includes fasting plasma glucose (mg/dL), gamma-glutamyl transferase (GGT, U/L), alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), total cholesterol (mg/dL), serum creatinine (mg/dL), urea (mg/dL), estimated glomerular filtration rate (eGFR, mL/min/1.73 m²), and complete blood count parameters measured according to standard laboratory units. The total number of laboratory abnormalities is defined as the count of laboratory parameters outside their corresponding reference intervals. For the purposes of this study, the total number of laboratory abnormalities serves as an operational indicator of biochemical risk.

The primary objective of the study is to evaluate the association between Five-Factor Personality Inventory (FFPI) personality trait scores and the total number of routine laboratory abnormalities identified during clinical evaluation.

Secondary analyses will examine associations between personality traits and glycemic status, fasting plasma glucose concentration, liver function markers (GGT, ALT, and AST), lipid profile parameters, renal function indicators, and the total number of laboratory abnormalities.

Data are collected prospectively during routine clinical practice. Statistical analyses will evaluate the strength and direction of associations between personality traits and laboratory health indicators while accounting for relevant demographic and clinical variables.

02

Conditions studied

  • Prediabetes
  • Hyperglycemia
  • Metabolic Syndrome

Keywords

  • Personality Traits
  • Biomarkers
  • Prediabetes
  • Hyperglycemia
  • Occupational Health
  • Five-Factor Personality Inventory
  • Laboratory Abnormalities
  • Routine Health Assessment
03

In context

Prediabetic State

918 studies on the registry are indexed under Prediabetic State; 232 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 224 across 129 observational studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Medical Center TOPMED is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults undergoing routine health assessment in a clinical setting who complete the Five-Factor Personality Inventory (FFPI) and have routine laboratory data available for evaluation of laboratory health indicators and their association with personality traits.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Undergoing routine health assessment
  • Completion of the Five-Factor Personality Inventory (FFPI)
  • Availability of routine laboratory test results
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years
  • Incomplete FFPI assessment
  • Missing or incomplete laboratory data
  • Refusal or inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Routine Health Assessment Cohort

    This cohort includes adults undergoing routine health assessment who complete the Five-Factor Personality Inventory (FFPI) and have biochemical laboratory data available from routine clinical evaluation. Collected variables include indicators of glycemic status, liver function, lipid metabolism, renal function, and complete blood count parameters obtained during routine laboratory assessment. Participants undergo routine laboratory assessment, and the total number of laboratory abnormalities is determined based on the count of laboratory parameters outside the corresponding reference intervals. These data are used to evaluate associations between personality traits and biological health indicators.

06

What researchers measure

Primary outcomes

  1. Number of Laboratory Abnormalities

    Total number of routine laboratory parameters outside their corresponding reference intervals, expressed as a count of abnormal laboratory findings. Laboratory parameters include fasting plasma glucose (mg/dL), gamma-glutamyl transferase (GGT, U/L), alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), total cholesterol (mg/dL), serum creatinine (mg/dL), urea (mg/dL), estimated glomerular filtration rate (eGFR, mL/min/1.73 m²), and complete blood count parameters measured according to standard laboratory units.

    Time frame: At baseline

Secondary outcomes

  1. Five-Factor Personality Inventory (FFPI) Scores

    Personality traits assessed using the Five-Factor Personality Inventory (FFPI), including Neuroticism, Extraversion, Agreeableness, Conscientiousness, and Openness dimensions, expressed as standardized questionnaire scores.

    Time frame: At baseline

  2. Glycemic Status

    Classification of participants according to fasting plasma glucose (mg/dL) concentration measured during routine laboratory assessment as: Normoglycemia (\<100 mg/dL) Prediabetes (100-125 mg/dL) Hyperglycemia (≥126 mg/dL or previously diagnosed diabetes mellitus)

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
  • Medical Center TOPMED
    Târgu Mureş, Mureș County 540058, Romania
    Recruiting
    • Stefania Diana Nilca, Principal Psychologist, PhD St · Contactdiana.nilca@umfst.ro · 0745404037
08

References and documents

Individual participant data

Plan to share: Undecided — Any future data sharing will be considered in accordance with institutional policies, ethical approvals, participant confidentiality requirements, and applicable data protection regulations.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653048
Lead sponsor
Medical Center TOPMED
Collaborators
George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Oct 1, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Stefania Diana St Nilca, Principal Psychologist, PhD St
Contact
diana.nilca@umfst.ro
+40745404037
Stefania Diana St Nilca, Principal Psychologist, PhD St
principal investigator · George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion